My disease is malaria Pick a nanoparticle you described in a previous assignment
ID: 56382 • Letter: M
Question
My disease is malaria Pick a nanoparticle you described in a previous assignment. Describe some of the different ways this nanoparticle could be functionalized to accumulate in your diseased tissue of interest. Would it be more beneficial to perform active or passive targeting? If you were to perform active targeting, what are 3 different tissue biomarkers you would try to target, and why? What sorts of targeting molecules would you put on the surface of your nanoparticle? What are your most important considerations when picking targeting molecules (size, charge, affinity, etc)? How do you expect this active targeting to change your overall nanoparticle accumulation in your tissue? If you were to perform passive targeting, what physical properties of your nanoparticle would you optimize, and why? How do you expect this passive targeting to change your overall nanoparticle accumulation in your tissue?My disease is malaria Pick a nanoparticle you described in a previous assignment. Describe some of the different ways this nanoparticle could be functionalized to accumulate in your diseased tissue of interest. Would it be more beneficial to perform active or passive targeting? If you were to perform active targeting, what are 3 different tissue biomarkers you would try to target, and why? What sorts of targeting molecules would you put on the surface of your nanoparticle? What are your most important considerations when picking targeting molecules (size, charge, affinity, etc)? How do you expect this active targeting to change your overall nanoparticle accumulation in your tissue? If you were to perform passive targeting, what physical properties of your nanoparticle would you optimize, and why? How do you expect this passive targeting to change your overall nanoparticle accumulation in your tissue?
My disease is malaria Pick a nanoparticle you described in a previous assignment. Describe some of the different ways this nanoparticle could be functionalized to accumulate in your diseased tissue of interest. Would it be more beneficial to perform active or passive targeting? If you were to perform active targeting, what are 3 different tissue biomarkers you would try to target, and why? What sorts of targeting molecules would you put on the surface of your nanoparticle? What are your most important considerations when picking targeting molecules (size, charge, affinity, etc)? How do you expect this active targeting to change your overall nanoparticle accumulation in your tissue? If you were to perform passive targeting, what physical properties of your nanoparticle would you optimize, and why? How do you expect this passive targeting to change your overall nanoparticle accumulation in your tissue?
Explanation / Answer
Different ways of nanoparticle fictionalization - The main aim of utilization of nanoparticle as drug vehicle is to protect drug against extracellular degradation, to achieve improved selectivity in target site. The fate of the nanoparticle is determined in vivo based on the capacity of the target tissue to recognize the nanoparticle as foreign body or whether it remain unnoticed. The level of its recognition is based on the character of the nanoparticle mainly on the cells which can interact with the nanoparticles.
In case of malaria it is based on the ability to remain in the blood stream for a prolonged period so that the interaction with RBC's and the parasite accumulated will increase.
Cell adhesion properties and the surface modification leads to increased efficacy. In treatment of cerebral malaria such kind of benefits are obtained by utilization of colloidal nanocarriers where the size of nanocarrier is < 1.000 nm.
Both passive and active targeting are being explored with malaria. Passive targeting is comparatively less promising in malaria since the target cells RBC's lack phagocytic and endocytic activity. Conventional nanocarriers for treating dormant parasite in hepatocytes more specifically in kupffer cells is an promising approach. This can be obtained by surface modification of nanoparticles with hydrophilic polymers such as PEG, so that it can delay phagocytosis where prolonged drug half life in the blood and increased contact with RBC can be achieved. Thus reduced protein adsorption and limited opsonization and complement activation is achieved. Apart from this cell specific ligands are also utilized for active targeting of the nano particles on specific target site.
Related Questions
drjack9650@gmail.com
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.